Result of AGM
Nuformix plc announced that all resolutions at its Annual General Meeting were passed, including the approval of the annual report and accounts for the year ended 30 September 2025, with 99.92% of votes in favour. Shareholders also approved the Annual Report on Remuneration with 99.84% in favour, and re-appointed directors Daniel Gooding, Julian Gilbert, and Madeleine Kennedy with strong support, receiving 99.85%, 99.85%, and 99.84% of votes respectively. The re-appointment of auditor Kreston Reeves LLP was approved by 99.73% of votes, and directors were authorised to determine auditor fees with 99.37% approval. Resolutions to authorise directors to allot shares and disapply pre-emption rights passed with 97.46% and 98.46% of votes respectively, while the company was authorised to purchase its own shares with 95.98% approval.
Select text to share a quote on X · sign in to keep highlights & notes in your NFX notes
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that the Annual General Meeting of Nuformix plc was held earlier today and all resolutions put to shareholders were duly passed and approved by a show of hands. The proxies received ahead of the AGM, are reported below:
| Resolution | Ordinary/ Special | For | Against | Total votes cast | Withheld | |||
|---|---|---|---|---|---|---|---|---|
| No. of votes | % | No. of votes | % | |||||
| 1 | To receive the annual report and accounts for the year ended 30 September 2025 | Ordinary | 214,955,860 | 99.92% | 177,416 | 0.08% | 215,133,276 | 8,248,030 |
| 2 | To approve the Annual Report on Remuneration | Ordinary | 220,295,243 | 99.84% | 357,453 | 0.16% | 220,652,696 | 2,728,610 |
| 3 | To re-appoint Daniel Gooding as a director | Ordinary | 220,637,188 | 99.85% | 327,691 | 0.15% | 220,964,879 | 2,416,427 |
| 4 | To re-appoint Julian Gilbert as a director | Ordinary | 220,625,354 | 99.85% | 339,525 | 0.15% | 220,964,879 | 2,416,427 |
| 5 | To re-appoint Madeleine Kennedy as a director | Ordinary | 217,650,945 | 99.84% | 347,691 | 0.16% | 217,998,636 | 5,382,670 |
| 6 | To re-appoint Kreston Reeves LLP as auditor | Ordinary | 220,393,106 | 99.73% | 605,530 | 0.27% | 220,998,636 | 2,382,670 |
| 7 | To authorise the Directors to determine the auditor's fees. | Ordinary | 219,520,242 | 99.37% | 1,398,865 | 0.63% | 220,919,107 | 2,462,199 |
| 8 | To authorise the Directors to allot shares. | Ordinary | 209,386,402 | 97.46% | 5,449,425 | 2.54% | 214,835,827 | 8,545,479 |
| 9 | To authorise the Directors to disapply pre-emption rights. | Special | 211,574,241 | 98.46% | 3,311,586 | 1.54% | 214,885,827 | 8,495,479 |
| 10 | To authorise the Company to purchase its own shares. | Special | 213,681,044 | 95.98% | 8,956,820 | 4.02% | 222,637,864 | 743,442 |
| 11 | To authorise calling of a general meeting on 14 clear days' notice. | Special | 222,647,463 | 99.88% | 277,416 | 0.12% | 222,924,879 | 456,427 |
The Company's issued share capital is 2,109,749,903 ordinary shares of £0.0005 each.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.